News
4 Oct 2021
Thermo Fisher Scientific Opens cGMP Plasmid DNA Manufacturing Facility in Carlsbad, California
Responding to critical market capacity constraints, Thermo Fisher announces the official opening of new 67,000 sqft cGMP plasmid DNA manufacturing facility in Carlsbad, CA. This site expands clinical and commercial capabilities for cGMP plasmid DNA used as a critical raw material to develop and manufacture cell and gene-based therapies in addition to capabilities to produce large-scale plasmid DNA as a primary drug substance for DNA therapies.
Accelerate development of plasmid-based medicines and vaccines
Mentioned Companies
Thermo Fisher Scientific Inc.
Related News
-
Sponsored Content CPHI Podcast Series: Ursatec – celebrating 30 years of pioneering preservative free
In the latest episode of the CPHI Podcast Series, Digital Editor Lucy Chard spoke with Dominik Rocchi of Ursatec. -
Sponsored Content How healthcare trends inform dosage forms
Capsules encompass one of the most popular solid oral dosage forms for pharmaceutical products, with the global empty capsule market predicted to rise to USD $3.7 billion by 2026. The growth in the capsule market can be partly attributed to the many op... -
Sponsored Content 2023 Pharma Trend Outlook: Innovation, Resilience, and Pharma 4.0
Download our 2023 Pharma Trends Outlook report to discover the trends set to shape the pharmaceutical landscape in the new year, with expert opinions and insight from across the pharmaceutical value chain. -
Sponsored Content CPHI Podcast Series: Key Considerations in Selecting the Right CMO Partner
In this month's episode we hear from Jayna Blake, Senior Project Manager for Technical Programs at Baxter BioPharma Solutions, on key considerations for successful CMO selection. -
Sponsored Content PharmaNutra announces new technology to combat iron deficiency
This oral solution allows for high iron absorption while minimising digestive issues -
Sponsored Content Size doesn’t matter: How smaller deals are shaping healthcare M&A
Several mega-deals have made a splash in the pharma and life sciences industries over recent years – from AstraZeneca’s acquisition of Alexion for $39 billion to Gilead Sciences’ $21 billion purchase of Immunomedics. With am... -
Sponsored Content Rise in home-based healthcare shaping pharma packaging and drug delivery
The pharma packaging and drug delivery industry has long been synonymous with rapid innovation. As medicine advances and patient needs change, so too should drug packaging and devices. This has been particularly evident during the pandem... -
Sponsored Content Biologics earmarked as opportunity in pharma packaging and drug delivery
The pharma packaging and drug delivery industry has gone through many evolutions, most notably to meet the challenges posed by the COVID-19 pandemic over the last two years. Disruptions to global supply chains posed a major issue, combined with a sharp...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance